The Bufei Nashen Pill Alleviates COPD by Targeting Endoplasmic Reticulum Stress Through the PERK/eIF2α Signaling Pathway
ABSTRACT Background Evidence supporting the therapeutic efficacy of Bufei Nashen pill (BFNSP) for chronic obstructive pulmonary disease (COPD) is currently limited. We evaluated BFNSP's effects on COPD progression and elucidated its potential mechanisms through LC/MS analysis of its active component...
محفوظ في:
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Wiley
2026-04-01
|
| سلاسل: | Immunity, Inflammation and Disease |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1002/iid3.70418 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|